The role of low-molecular-weight heparin in the management of acute coronary syndromes (Q33347022)

26 July 2017

1 reference

title

The role of low-molecular-weight heparin in the management of acute coronary syndromes (English)

1 reference

26 July 2017

1 reference

acute coronary syndrome

1 reference

Marc Cohen

1

1 reference

PubMed ID

12644342

26 July 2017

language of work or name

English

0 references

publication date

1 February 2003

1 reference

Journal of the American College of Cardiology

26 July 2017

1 reference

26 July 2017

41

1 reference

26 July 2017

4 Suppl S

1 reference

26 July 2017

55S-61S

1 reference

ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the M

26 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902901-7

7 January 2021

Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902901-7

7 January 2021

Low-molecular-weight heparins

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902901-7

7 January 2021

A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902901-7

7 January 2021

Can we differentiate the low-molecular-weight heparins?

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902901-7

7 January 2021

A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902901-7

7 January 2021

Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease: one-year results of the ESSENCE Study. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q Wave Coronary Events

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902901-7

7 January 2021

Low molecular weight heparin decreases rebound ischemia in unstable angina or non-Q-wave myocardial infarction: the Canadian ESSENCE ST segment monitoring substudy

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902901-7

7 January 2021

Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902901-7

7 January 2021

Prior aspirin users with acute non-ST-elevation coronary syndromes are at increased risk of cardiac events and benefit from enoxaparin

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902901-7

7 January 2021

Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 11B-ESSENCE meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902901-7

7 January 2021

Superiority of enoxaparin versus unfractionated heparin for unstable angina/non-Q-wave myocardial infarction regardless of activated partial thromboplastin time

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902901-7

7 January 2021

Economic assessment of low-molecular-weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome patients: results from the ESSENCE randomized trial. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q wave Coronary Even

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902901-7

7 January 2021

Cost-effectiveness analysis of enoxaparin versus unfractionated heparin for acute coronary syndromes. A Canadian hospital perspective

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902901-7

7 January 2021

Economic evaluation of enoxaparin sodium versus heparin in unstable angina. A French sub-study of the ESSENCE trial

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902901-7

7 January 2021

Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: the FRISC II invasive randomised trial. FRISC II Investigators. Fast Revascularisation during Instability in Coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902901-7

7 January 2021

Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study (FRIC)

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902901-7

7 January 2021

Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAX.I.S. (FRAxiparine in

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902901-7

7 January 2021

Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902901-7

7 January 2021

Abciximab. An updated review of its use in ischaemic heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902901-7

7 January 2021

Tirofiban. A review of its use in acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902901-7

7 January 2021

Eptifibatide: a review of its use in patients with acute coronary syndromes and/or undergoing percutaneous coronary intervention

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902901-7

7 January 2021

Percutaneous coronary intervention after subcutaneous enoxaparin pretreatment in patients with unstable angina pectoris

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902901-7

7 January 2021

Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902901-7

7 January 2021

Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902901-7

7 January 2021

Usefulness of intravenous enoxaparin for percutaneous coronary intervention in stable angina pectoris

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902901-7

7 January 2021

Dalteparin in combination with abciximab during percutaneous coronary intervention

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902901-7

7 January 2021

Local delivery of enoxaparin to decrease restenosis after stenting: results of initial multicenter trial: Polish-American Local Lovenox NIR Assessment study (The POLONIA study)

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902901-7

7 January 2021

Combination therapy with tirofiban and enoxaparin in acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902901-7

7 January 2021

Randomized comparison of enoxaparin, a low-molecular-weight heparin, with unfractionated heparin adjunctive to recombinant tissue plasminogen activator thrombolysis and aspirin: second trial of Heparin and Aspirin Reperfusion Therapy (HART II)

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902901-7

7 January 2021

A synthetic factor-Xa inhibitor (ORG31540/SR9017A) as an adjunct to fibrinolysis in acute myocardial infarction. The PENTALYSE study

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902901-7

7 January 2021

Randomized trial of low molecular weight heparin (dalteparin) in prevention of left ventricular thrombus formation and arterial embolism after acute anterior myocardial infarction: the Fragmin in Acute Myocardial Infarction (FRAMI) Study

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902901-7

7 January 2021

Low molecular weight heparin (dalteparin) as adjuvant treatment of thrombolysis in acute myocardial infarction--a pilot study: biochemical markers in acute coronary syndromes (BIOMACS II).

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902901-7

7 January 2021

Randomized comparison of direct thrombin inhibition versus heparin in conjunction with fibrinolytic therapy for acute myocardial infarction: results from the GUSTO-IIb Trial. Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coron

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902901-7

7 January 2021

The low-molecular-weight heparin dalteparin as adjuvant therapy in acute myocardial infarction: the ASSENT PLUS study

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902901-7

7 January 2021

Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902901-7

7 January 2021

Treatment and outcome of myocardial infarction in hospitals with and without invasive capability. Investigators in the National Registry of Myocardial Infarction.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902901-7

7 January 2021

The TETAMI trial: the safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and of tirofiban versus placebo in the treatment of acute myocardial infarction for patients not thrombolyzed: methods and design

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902901-7

7 January 2021

10.1016/S0735-1097(02)02901-7

Identifiers

DOI

1 reference

26 July 2017

1 reference

PubMed ID

12644342